(-0.22%) 5 201.25 points
(-0.14%) 39 139 points
(-0.31%) 18 130 points
(0.66%) $79.51
(-0.23%) $2.18
(-0.20%) $2 317.70
(0.76%) $27.81
(0.49%) $989.40
(0.16%) $0.932
(0.19%) $10.91
(0.18%) $0.802
(0.46%) $92.16
0.07% $ 28.00
Live Chart Being Loaded With Signals
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform...
Stats | |
---|---|
Dzisiejszy wolumen | 1.42M |
Średni wolumen | 1.94M |
Kapitalizacja rynkowa | 1.77B |
EPS | $0 ( 2024-04-04 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 66.67 |
ATR14 | $0.381 (1.36%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-11 | O'connor Daniel J. | Buy | 750 000 | Common Stock |
2023-10-27 | O'connor Daniel J. | Sell | 50 012 | Common Stock |
2023-10-23 | Cormorant Asset Management, Lp | Buy | 1 307 311 | Common Stock |
2023-09-18 | Cormorant Asset Management, Lp | Buy | 751 233 | Ordinary Shares |
2023-09-15 | Cormorant Asset Management, Lp | Buy | 1 401 505 | Ordinary Shares |
INSIDER POWER |
---|
64.48 |
Last 64 transactions |
Buy: 36 374 710 | Sell: 11 079 608 |
Wolumen Korelacja
Ambrx Biopharma Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
MSP | 0.95 |
RXN | 0.934 |
UVE | 0.934 |
MOG-B | 0.927 |
KDMN | 0.925 |
DCT | 0.922 |
WST | 0.921 |
AIW | 0.918 |
BGSX | 0.915 |
FCN | 0.914 |
10 Najbardziej negatywne korelacje | |
---|---|
LUMN | -0.94 |
KT | -0.934 |
AFI | -0.926 |
QGEN | -0.924 |
GEO | -0.92 |
NSC | -0.917 |
EQC | -0.912 |
UBA | -0.907 |
ATTO | -0.907 |
PDS | -0.906 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ambrx Biopharma Inc. Korelacja - Waluta/Towar
Ambrx Biopharma Inc. Finanse
Annual | 2022 |
Przychody: | $7.40M |
Zysk brutto: | $7.40M (100.00 %) |
EPS: | $-2.02 |
FY | 2022 |
Przychody: | $7.40M |
Zysk brutto: | $7.40M (100.00 %) |
EPS: | $-2.02 |
FY | 2021 |
Przychody: | $7.46M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-3.36 |
FY | 2020 |
Przychody: | $13.67M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.439 |
Financial Reports:
No articles found.
Ambrx Biopharma Inc.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej